Parkinson Disease

Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.

[1]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  D. Brooks,et al.  Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. , 2020, Brain : a journal of neurology.

[3]  V. Gradinaru,et al.  Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice , 2020, Nature Neuroscience.

[4]  Nikhil Panicker,et al.  Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease , 2019, Neuron.

[5]  H. McBride,et al.  Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1−/− mice , 2019, Nature.

[6]  W. V. van IJcken,et al.  Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes , 2019, Nature Neuroscience.

[7]  S. Mantri,et al.  State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease , 2019, npj Parkinson's Disease.

[8]  S. Purdy,et al.  Gavel Club for people with aphasia: communication confidence and quality of communication life , 2019 .

[9]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[10]  H. Cai,et al.  Parkin and PINK1 mitigate STING-induced inflammation , 2018, Nature.

[11]  H. Chong,et al.  Individual Therapeutic Singing Program for Vocal Quality and Depression in Parkinson’s Disease , 2018, Journal of movement disorders.

[12]  Xiang Gao,et al.  Non-motor features of Parkinson’s disease in a nested case–control study of US men , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[13]  J. Kulisevsky,et al.  Update in therapeutic strategies for Parkinson's disease , 2018, Current opinion in neurology.

[14]  T. Postmus Genetics of Parkinson's disease , 2018 .

[15]  Avril Lee,et al.  Medicine Administration in People with Parkinson’s Disease in New Zealand: An Interprofessional, Stakeholder-Driven Online Survey , 2018, Dysphagia.

[16]  G. Oyama,et al.  Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation , 2018, BMJ Case Reports.

[17]  P. Videira,et al.  Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease , 2018, Front. Neurosci..

[18]  Sung-Rae Cho,et al.  Relationship Between Swallowing Function and Maximum Phonation Time in Patients With Parkinsonism , 2018, Annals of rehabilitation medicine.

[19]  Z. Mari,et al.  Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease , 2018, Nature Medicine.

[20]  P. Warnke,et al.  Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  Toshiyuki Yamamoto,et al.  Dysphagia Causes Symptom Fluctuations after Oral L-DOPA Treatment in a Patient with Parkinson Disease , 2018, Case Reports in Neurology.

[22]  R. Pahwa,et al.  The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients. , 2018, Neurodegenerative disease management.

[23]  Mariana Aurora Cansino-Torres,et al.  Allergy to Carbidopa , 2018, Clinical neuropharmacology.

[24]  P. Hobson,et al.  Mortality and quality of death certification in a cohort of patients with Parkinson’s disease and matched controls in North Wales, UK at 18 years: a community-based cohort study , 2018, BMJ Open.

[25]  Anna Miles,et al.  Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study , 2017, Journal of the Neurological Sciences.

[26]  C. Barlow,et al.  Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson's disease. , 2017, Parkinsonism & related disorders.

[27]  J. Assmus,et al.  Glitazone use associated with reduced risk of Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.

[28]  L. Segall The effect of group singing on the voice and swallow function of healthy, sedentary, older adults: A pilot study , 2017 .

[29]  Satoshi Morita,et al.  Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model , 2017, Nature.

[30]  J. C. Vest,et al.  Lumbee traditional medicine: Neuroprotective activities of medicinal plants used to treat Parkinson's disease-related symptoms. , 2017, Journal of ethnopharmacology.

[31]  N. Hattori,et al.  Clinical evaluation of ropinirole controlled-release formulation at 18-24 mg/day in Japanese patients with Parkinson's disease. , 2017, Parkinsonism & related disorders.

[32]  C. Marini,et al.  Obstructive sleep apnea syndrome in Parkinson's disease and other parkinsonisms. , 2017, Functional neurology.

[33]  Annelise Ayres,et al.  The Impact of Deep Brain Stimulation on the Quality of Life and Swallowing in Individuals with Parkinson's Disease , 2017, International Archives of Otorhinolaryngology.

[34]  Nir Giladi,et al.  A randomized trial of a low‐dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.

[35]  Sanghee Moon,et al.  Qigong Exercise May Reduce Serum TNF-α Levels and Improve Sleep in People with Parkinson’s Disease: A Pilot Study , 2017, Medicines.

[36]  E. Stegemöller,et al.  Therapeutic singing as an early intervention for swallowing in persons with Parkinson's disease. , 2017, Complementary therapies in medicine.

[37]  C. Sapienza,et al.  Effects of singing on voice, respiratory control and quality of life in persons with Parkinson’s disease , 2017, Disability and rehabilitation.

[38]  L. Vécsei,et al.  Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy , 2017, Drug design, development and therapy.

[39]  N. Chen,et al.  Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation. , 2017, Toxicology letters.

[40]  T. Warnecke,et al.  Esophageal dysfunction in different stages of Parkinson's disease , 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[41]  O. Tysnes,et al.  Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease , 2016, Nature Communications.

[42]  N. Osada,et al.  Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test. , 2016, Parkinsonism & related disorders.

[43]  Aline Aparecida Foppa,et al.  Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study , 2016, Neurology and Therapy.

[44]  S. Purdy,et al.  Choral singing therapy following stroke or Parkinson’s disease: an exploration of participants’ experiences , 2016, Disability and rehabilitation.

[45]  B. Kremer,et al.  Voice‐ and swallow‐related quality of life in idiopathic Parkinson's disease , 2016, The Laryngoscope.

[46]  T. Warnecke,et al.  Dysphagia in Parkinson’s Disease , 2016, Dysphagia.

[47]  D. Novakovic,et al.  Adult obstructive sleep apnoea and the larynx , 2015, Current opinion in otolaryngology & head and neck surgery.

[48]  D. Maltête,et al.  Impact of deep brain stimulation on pharyngo‐esophageal motility: a randomized cross‐over study , 2015, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[49]  H. Sawada,et al.  Impact of Aspiration Pneumonia on the Clinical Course of Progressive Supranuclear Palsy: A Retrospective Cohort Study , 2015, PloS one.

[50]  Krupa Patel Optimising medication for Parkinson's disease patients with dysphagia. , 2015, British journal of community nursing.

[51]  Nicole C. Swann,et al.  Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson's disease , 2015, Nature Neuroscience.

[52]  S. Daniels,et al.  Dysphagia Management in Stroke Rehabilitation , 2014, Current Physical Medicine and Rehabilitation Reports.

[53]  B. Kremer,et al.  Treatment effects for dysphagia in Parkinson's disease: a systematic review. , 2014, Parkinsonism & related disorders.

[54]  Richard D. Jones,et al.  Skill training for swallowing rehabilitation in patients with Parkinson's disease. , 2014, Archives of physical medicine and rehabilitation.

[55]  R. Soose,et al.  What is the role of the larynx in adult obstructive sleep apnea? , 2014, The Laryngoscope.

[56]  Tejas Sankar,et al.  Deep brain stimulation for Parkinson's disease and other movement disorders. , 2013, Current opinion in neurology.

[57]  H. Shill,et al.  Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. , 2013, Journal of neuropathology and experimental neurology.

[58]  T. Cunha-Oliveira,et al.  Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. , 2012, Free radical biology & medicine.

[59]  T. Dawson,et al.  Animal models of Parkinson's disease: vertebrate genetics. , 2012, Cold Spring Harbor perspectives in medicine.

[60]  F. Baker,et al.  The effect of group music therapy on mood, speech, and singing in individuals with Parkinson's disease--a feasibility study. , 2012, Journal of music therapy.

[61]  D. Surmeier,et al.  Physiological phenotype and vulnerability in Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[62]  A. Brice,et al.  What genetics tells us about the causes and mechanisms of Parkinson's disease. , 2011, Physiological reviews.

[63]  K. Tieu,et al.  A guide to neurotoxic animal models of Parkinson's disease. , 2011, Cold Spring Harbor perspectives in medicine.

[64]  Graham K Kerr,et al.  Prevalence of malnutrition in Parkinson's disease: a systematic review. , 2011, Nutrition reviews.

[65]  C. Goetz The history of Parkinson's disease: early clinical descriptions and neurological therapies. , 2011, Cold Spring Harbor perspectives in medicine.

[66]  Shimon Sapir,et al.  Intensive voice treatment in Parkinson’s disease: Lee Silverman Voice Treatment , 2011, Expert review of neurotherapeutics.

[67]  Miguel Ángel Martínez,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[68]  M. Okun,et al.  Aspiration and swallowing in Parkinson disease and rehabilitation with EMST , 2010, Neurology.

[69]  D. Yang,et al.  The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[70]  Roy W Jones,et al.  Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[71]  T. Südhof,et al.  α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.

[72]  Anatol C. Kreitzer,et al.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.

[73]  E. Ringelstein,et al.  Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy , 2010, Movement disorders : official journal of the Movement Disorder Society.

[74]  H. Reichmann Clinical Criteria for the Diagnosis of Parkinson’s Disease , 2010, Neurodegenerative Diseases.

[75]  T. Schallert,et al.  Targeted exercise therapy for voice and swallow in persons with Parkinson's disease , 2010, Brain Research.

[76]  S. Mandel,et al.  Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy , 2010, EPMA Journal.

[77]  M. Farrer,et al.  Missing pieces in the Parkinson's disease puzzle , 2010, Nature Medicine.

[78]  Christy L Ludlow,et al.  Electrical neuromuscular stimulation in dysphagia: current status , 2010, Current opinion in otolaryngology & head and neck surgery.

[79]  Marc Cruts,et al.  Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update , 2010, Human mutation.

[80]  M. Cookson,et al.  Parkinson's disease: insights from pathways. , 2010, Human molecular genetics.

[81]  A. Abeliovich Parkinson's disease: Mitochondrial damage control , 2010, Nature.

[82]  J. Ostrem,et al.  OVERVIEW OF COMMON MOVEMENT DISORDERS , 2010, Continuum.

[83]  Atsushi Tanaka,et al.  PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.

[84]  A. Lang,et al.  Hereditary parkinsonism: Parkinson disease look‐alikes—An algorithm for clinicians to “PARK” genes and beyond , 2009, Movement disorders : official journal of the Movement Disorder Society.

[85]  M. Okun,et al.  The relationship between quality of life and swallowing in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[86]  M. Okun,et al.  Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. , 2009, Chest.

[87]  A. Zapf,et al.  Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias , 2009, European journal of neurology.

[88]  M. Dafotakis,et al.  Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis , 2009, Journal of Clinical Neuroscience.

[89]  Grant D. Huang,et al.  Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. , 2009, JAMA.

[90]  P. Haggard Human volition: towards a neuroscience of will , 2008, Nature Reviews Neuroscience.

[91]  S. Jick,et al.  Use of antihypertensives and the risk of Parkinson disease , 2008, Neurology.

[92]  Hitoshi Takahashi,et al.  α-Synuclein pathology in the neostriatum in Parkinson’s disease , 2008, Acta Neuropathologica.

[93]  C. Tanner,et al.  Association of olfactory dysfunction with risk for future Parkinson's disease , 2008, Annals of neurology.

[94]  J. Nutt,et al.  Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk , 2008, Movement disorders : official journal of the Movement Disorder Society.

[95]  M. Weisskopf,et al.  Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[96]  M. Kringelbach,et al.  Translational principles of deep brain stimulation , 2007, Nature Reviews Neuroscience.

[97]  Jennifer L. Spielman,et al.  Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. , 2007, Journal of speech, language, and hearing research : JSLHR.

[98]  L. Skipper,et al.  Pathogenic mutations in Parkinson disease , 2007, Human mutation.

[99]  D. James Surmeier,et al.  ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease , 2007, Nature.

[100]  D. Nicholl,et al.  Genetics of Parkinson’s disease and parkinsonism , 2007, Expert review of neurotherapeutics.

[101]  Di Chen,et al.  The proteasome as a potential target for novel anticancer drugs and chemosensitizers. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[102]  L. Ramig,et al.  The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. , 2006, Seminars in speech and language.

[103]  L. Ramig,et al.  The Lee Silverman Voice Treatment® for voice, speech and other orofacial disorders in patients with Parkinson’s disease , 2006 .

[104]  M. Farrer Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[105]  G. Bing,et al.  Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease , 2006, Journal of Neuroinflammation.

[106]  N. Wood,et al.  Expanding insights of mitochondrial dysfunction in Parkinson's disease , 2006, Nature Reviews Neuroscience.

[107]  N. Wood,et al.  Molecular genetic pathways in Parkinson's disease: a review. , 2005, Clinical science.

[108]  Nir Giladi,et al.  A Group Intervention Model for Speech and Communication Skills in Patients With Parkinson's Disease , 2005 .

[109]  Yue Huang,et al.  Genetic contributions to Parkinson's disease , 2004, Brain Research Reviews.

[110]  M. Vila,et al.  Genetic clues to the pathogenesis of Parkinson's disease , 2004, Nature Medicine.

[111]  A. Schober,et al.  Genes, proteins, and neurotoxins involved in Parkinson’s disease , 2004, Progress in Neurobiology.

[112]  L. Ramig,et al.  Parkinson's disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment. , 2004, Seminars in speech and language.

[113]  Tatiana Foroud,et al.  Genetics of Parkinson disease , 2004, Genetics in Medicine.

[114]  Lorene M Nelson,et al.  Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. , 2003, American journal of epidemiology.

[115]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[116]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[117]  Jeri Logemann,et al.  Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study , 2002, INTERSPEECH.

[118]  S. Countryman,et al.  Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up , 2001 .

[119]  C. Tanner,et al.  Frequency of bowel movements and the future risk of Parkinson’s disease , 2001, Neurology.

[120]  J Q Trojanowski,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[121]  S. Countryman,et al.  Changes in vocal loudness following intensive voice treatment (LSVT®) in individuals with Parkinson's disease: A comparison with untreated patients and normal age‐matched controls , 2001, Movement disorders : official journal of the Movement Disorder Society.

[122]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[123]  E. Quigley,et al.  Cricopharyngeal dysfunction in Parkinson's disease: Role in dysphagia and response to myotomy , 1996, Movement disorders : official journal of the Movement Disorder Society.

[124]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[125]  O. Hornykiewicz,et al.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.

[126]  Jung-Hoon Lee,et al.  Effects of neuromuscular electrical stimulation in patients with Parkinson's disease and dysphagia: A randomized, single-blind, placebo-controlled trial. , 2018, NeuroRehabilitation.

[127]  A. Wehr,et al.  Effects of a formal exercise program on Parkinson's disease: a pilot study using a delayed start design. , 2014, Parkinsonism & related disorders.

[128]  M. Okun,et al.  Detraining outcomes with expiratory muscle strength training in Parkinson disease. , 2014, Journal of rehabilitation research and development.

[129]  J. Girault Signaling in striatal neurons: the phosphoproteins of reward, addiction, and dyskinesia. , 2012, Progress in molecular biology and translational science.

[130]  W. Schmidt,et al.  Vaccination for Parkinson's disease. , 2012, Parkinsonism & related disorders.

[131]  Christine Klein,et al.  Genetics of Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[132]  David J Brooks,et al.  Parkinson's disease: diagnosis. , 2012, Parkinsonism & related disorders.

[133]  J. Stockman Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .

[134]  R. Youle,et al.  Mechanisms of mitophagy , 2010, Nature Reviews Molecular Cell Biology.

[135]  R. Burgoyne,et al.  Chaperoning the SNAREs: a role in preventing neurodegeneration? , 2010, Nature Cell Biology.

[136]  A. Singleton Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. , 2005, Trends in neurosciences.

[137]  M. Vila,et al.  Neurological diseases: Targeting programmed cell death in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.

[138]  J. Ghika [Genetics of parkinsonism]. , 2000, Revue medicale de la Suisse romande.

[139]  M. C. Kagel,et al.  Pharyngo-Esophageal Dysphagia in Parkinson's Disease , 1997, Dysphagia.